System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Epublish

PubMed: 40573382 DOI: 10.3390/v17060792

Antiviral Intervention of COVID-19: Linkage of Disease Severity with Genetic Markers FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760).

Viruses 17(6)

Authors: Maksym Sokolenko, Larysa Sydorchuk, Alina Sokolenko, Ruslan Sydorchuk, Iryna Kamyshna, Andriy Sydorchuk, Ludmila Sokolenko, Oleksandr Sokolenko, Valentyn Oksenych, Oleksandr Kamyshnyi

Affiliations

  • Department of Infectious Diseases and Epidemiology, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.
  • Department of Family Medicine, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.
  • Department of Surgery No 2, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.
  • Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.
  • Donauklinik, 89231 Neu Ulm, Germany.
  • Department of Medical and Biological Fundamentals of Physical Culture, Pavlo Tychyna Uman State Pedagogical University, 20300 Uman, Ukraine.
  • Department of Infectious Diseases, Bukovinian State Medical University, 58012 Chernivtsi, Ukraine.
  • Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.
  • Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.

Abstract

The purpose of this study was to investigate polymorphic variants of the genes FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760) in patients with SARS-CoV-2 and to determine their role in the COVID-19 severity course against the background of antiviral therapy. Real-time polymerase chain reaction (RT-PCR) was used to genotype the polymorphism of the selected genes. GS-5734 (remdesivir) was prescribed as the basic antiviral drug. Binary logistic regression confirmed a low probability of COVID-19 developing in carriers of the A-allele of the FGB gene. The highest probability of moderate and severe COVID-19 clinical forms developing was found in G-allele carriers (especially the GG genotype) of the FGB gene (rs1800790) and the T-allele of the TMPRSS2 gene (rs12329760). Antiviral drug GS-5734 (remdesivir) administration with anti-inflammatory therapy reduces the TMPRSS2 blood level in moderate COVID-19, IL-6 in severe COVID-19 course, and fibrinogen A- and D-dimers in both groups. The proposed treatment does not significantly affect the concentration of endothelin-1, but a decrease in procalcitonin associated with additional antibacterial use was observed, especially in severe COVID-19.

MeSH

Genes, Pharmaceutical Preparations, Probability, Polymerase Chain Reaction, Virology, Covid-19, Alleles, Genotype, Therapeutics, Genetic Markers, Antiviral Agents